{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:27:14Z","timestamp":1793158034166,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p><jats:sup>18<\/jats:sup>F-APN-1607 is a novel tau positron emission tomography (PET) tracer characterized with high binding affinity for 3\u2212 and 4-repeat tau deposits. The aim was to analyze the spatial distribution of <jats:sup>18<\/jats:sup>F-APN-1607 PET imaging in Alzheimer\u2019s disease (AD) subjects with different stages and to investigate the relationship between the change of tau deposition and overall disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed the <jats:sup>18<\/jats:sup>F-APN-1607 PET imaging of 31 subjects with clinically and imaging defined as AD. According to the Mini-Mental State Examination (MMSE) score, patients were divided into three groups, namely, mild (\u226521, <jats:italic>n<\/jats:italic> = 7), moderate (10\u201320, <jats:italic>n<\/jats:italic> = 16), and severe (\u22649, <jats:italic>n<\/jats:italic> = 8). PET imaging was segmented to 70 regions of interest (ROIs) and extracted the standard uptake value (SUV) of each ROI. SUV ratio (SUVR) was calculated from the ratio of SUV in different brain regions to the cerebellar cortex. The regions were defined as positive and negative with unsupervised cluster analysis according to SUVR. The SUVRs of each region were compared among groups with the one-way ANOVA or Kruskal\u2013Wallis <jats:italic>H<\/jats:italic> test. Furthermore, the correlations between MMSE score and regional SUVR were calculated with Pearson or Spearman correlation analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant differences among groups in gender (\u03c7<jats:sup>2<\/jats:sup> = 3.814, <jats:italic>P<\/jats:italic> = 0.161), age of onset (<jats:italic>P<\/jats:italic> = 0.170), age (<jats:italic>P<\/jats:italic> = 0.109), and education level (<jats:italic>P<\/jats:italic> = 0.065). With the disease progression, the <jats:sup>18<\/jats:sup>F-APN-1607 PET imaging showed the spread of tau deposition from the hippocampus, posterior cingulate gyrus (PCG), and lateral temporal cortex (LTC) to the parietal and occipital lobes, and finally to the frontal lobe. Between the mild and moderate groups, the main brain areas with significant differences in <jats:sup>18<\/jats:sup>F-APN-1607 uptake were supplementary motor area (SMA), cuneus, precuneus, occipital lobule, paracentral lobule, right angular gyrus, and parietal, which could be used for early disease progression assessment (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). There were significant differences in the frontal lobe, right temporal lobe, and fusiform gyrus between the moderate and severe groups, which might be suitable for the late-stage disease progression assessment (<jats:italic>P<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:sup>18<\/jats:sup>F-APN-1607 PET may serve as an effective imaging marker for visualizing the change pattern of tau protein deposition in AD patients, and its uptake level in certain brain regions is closely related to the severity of cognitive impairment. These indicate the potential of <jats:sup>18<\/jats:sup>F-APN-1607 PET for the <jats:italic>in vivo<\/jats:italic> evaluation of the progression of AD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2021.789054","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T16:23:13Z","timestamp":1644510193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer\u2019s Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaojun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihou","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00149","article-title":"The Influence of Baseline Alzheimer\u2019s Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.","volume":"11","author":"Abdullah","year":"2020","journal-title":"Front. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1097\/RLU.0000000000002791","article-title":"In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition.","volume":"44","author":"Baghel","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of Alzheimer\u2019s disease-related neurofibrillary changes.","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023630","article-title":"Potential Pathways of Abnormal Tau and \u03b1-Synuclein Dissemination in Sporadic Alzheimer\u2019s and Parkinson\u2019s Diseases.","volume":"8","author":"Braak","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","article-title":"Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment.","volume":"40","author":"Chandra","year":"2019","journal-title":"Hum. Brain Mapp."},{"key":"B7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-pet and 18f-fdg-pet in the diagnostic investigation of alzheimer\u2019s disease and other dementias.","volume":"19","author":"Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00685-4","article-title":"Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer\u2019s disease.","volume":"12","author":"Cho","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.","volume":"80","author":"Cho","year":"2016","journal-title":"Anna. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jalz.2019.05.009","article-title":"In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals.","volume":"15","author":"Das","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatric Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00636-z","article-title":"The dynamics of biomarkers across the clinical spectrum of Alzheimer\u2019s disease.","volume":"12","author":"Hadjichrysanthou","year":"2020","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ajmg.b.32836","article-title":"Genetic study of young-onset dementia using targeted gene panel sequencing in Taiwan","volume":"186","author":"Hsu","year":"2021","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/RLU.0000000000003164","article-title":"The Imaging Features and Clinical Associations of a Novel Tau PET Tracer-18F-APN1607 in Alzheimer Disease.","volume":"45","author":"Hsu","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"B16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.749649","article-title":"Performance of plasma amyloid \u03b2, total tau, and neurofilament light chain in the identification of probable Alzheimer\u2019s disease in South China","volume":"13","author":"Jiao","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00212","article-title":"The Validation of Multifactor Model of Plasma A\u03b2 42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease.","volume":"12","author":"Jiao","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JAD-170129","article-title":"PET Tau and Amyloid-\u03b2 Burden in Mild Alzheimer\u2019s Disease: divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.","volume":"60","author":"Koychev","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1109\/3477.764879","article-title":"Genetic K-means algorithm.","volume":"29","author":"Krishna","year":"1999","journal-title":"IEEE Trans. Syst. Man. Cybern. C Appl. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures.","volume":"16","author":"Longhe","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"B22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2967\/jnumed.117.201632","article-title":"Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models.","volume":"59","author":"Ni","year":"2018","journal-title":"J. Nucl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00259-020-05099-w","article-title":"The impact of demographic, clinical, genetic, and imaging variables on tau PET status.","volume":"48","author":"Ossenkoppele","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","article-title":"Protein transmission in neurodegenerative disease.","volume":"16","author":"Peng","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/brain\/aww334","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.","volume":"140","author":"Pontecorvo","year":"2017","journal-title":"Brain J. Neurol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00648-8","article-title":"Regional SUV quantification in hybrid PET\/MR, a comparison of two atlas-based automatic brain segmentation methods.","volume":"10","author":"Ruan","year":"2020","journal-title":"EJNMMI Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1007\/s00259-020-05183-1","article-title":"Indication of retrograde tau spreading along Braak stages and functional connectivity pathways.","volume":"48","author":"Seemiller","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer\u2019s and Non-Alzheimer\u2019s Disease Tauopathies.","volume":"109","author":"Tagai","year":"2021","journal-title":"Neuron"},{"key":"B29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neurobiolaging.2019.05.026","article-title":"Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer\u2019s disease.","volume":"81","author":"Teng","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030061","article-title":"Molecular and Imaging Biomarkers in Alzheimer\u2019s Disease: a Focus on Recent Insights.","volume":"10","author":"Villa","year":"2020","journal-title":"J. Pers. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-013-2681-7","article-title":"In vivo evaluation of a novel tau imaging tracer for Alzheimer\u2019s disease.","volume":"41","author":"Villemagne","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease.","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25071750","article-title":"Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy.","volume":"25","author":"Weng","year":"2020","journal-title":"Molecules"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00486","article-title":"Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults.","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Neurol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.789054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T16:23:16Z","timestamp":1644510196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.789054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":34,"alternative-id":["10.3389\/fnagi.2021.789054"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.789054","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"article-number":"789054"}}